Medicine focus

Categories
  1. Lurbinectedin for Ewing sarcoma and neuroendocrine tumors: Are we there yet?

    Can lurbinectedin be used to treat Ewing sarcoma and neuroendocrine tumors? The latest data and likely approval timelines.

    Read more »
  2. Relyvrio Discontinued: Top Alternatives and How to Continue Your Treatment

    Relyvrio is being pulled off the market. What does it mean for you and your treatment?

    Read more »
  3. Who is a candidate for lecanemab (and how to get the treatment if you qualify)?

    Who qualifies for treatment with lecanemab? And how non-US patients can get the medicine if their doctor prescribes it.

    Read more »
  4. Fruquintinib for gastric cancer: Will it be approved soon?

    Fruquintinib clinical trials in gastric cancer are showing promising results. Will the medicine be approved for this indication soon?

    Read more »
  5. Lurbinectedin's EMA approval: Is it coming (and when)?

    Will Zepzelca be available to European and UK patients soon? Here's what we know, and your options if you can't wait.

    Read more »
  6. Givinostat's role in polycythemia vera treatment: All you need to know

    Can givinostat be used to treat polycythemia vera? Here's what clinical trial data show.

    Read more »
  7. Givinostat's EMA approval: How long do you have to wait (and how not to)?

    When will the new nonsteroidal treatment for Duchenne be available in the EU and the UK?

    Read more »
  8. What types of cancer can Tivdak treat? The latest trial data.

    Could Tivdak treat more than cervical cancer? Here's the latest overview of trials focusing on ovarian, head and neck cancers, and more.

    Read more »
  9. Eflornithine for neuroblastoma: EMA approval timelines and how to avoid waiting

    When will European patients have access to the newest FDA-approved neuroblastoma treatment?

    Read more »
  10. Iptacopan's EMA approval is near. When will the medicine be available to you?

    Iptacopan will soon be approved in Europe, but when will it be available to patients?

    Read more »
  11. Retifanlimab for renal cell carcinoma (and other types of cancer)

    Zynyz(retifanlimab) may have a larger role to play in cancer treatment. Find out the latest research in renal cell carcinoma and more.

    Read more »
  12. Everything about eplontersen's EMA approval (and how to get the treatment sooner)

    When will Wainua be available to patients in Europe and the UK? The latest news and all your options in the meantime.

    Read more »
  13. What types of cancer can toripalimab treat?

    Toripalimab is being studied as a treatment of NSCLC, oesophageal cancer, melanoma, and more. What does research tell us, and what does it mean for you?

    Read more »
  14. Can erdafitinib treat breast cancer? The latest data, in simple terms.

    Can Balversa be used to treat breast cancer? What we know from research, and what it means for you.

    Read more »
  15. When is toripalimab getting its EMA approval (and how not to wait)

    Toripalimab may get its EMA and MHRA approvals soon, but when will it be available to patients? All you need to know.

    Read more »
  16. Tivdak's EMA approval: When is it coming (and what to do if you can't wait)

    When will Tivdak be available to patients in Europe and the UK? All you need to know, and all your options to get the treatment quicker.

    Read more »
  17. Zynyz's EMA approval: When will the treatment be available (and how not to wait)

    Zynyz is close to EMA approval, but it won't be immediately available everywhere in Europe. Here's how to get the treatment at your own timeline.

    Read more »
  18. Erdafitinib's EMA approval: Where are we five years after its first global approval

    Erdafitinib may get its EMA approval in 2024, but when will it be available on the market?

    Waiting for erdafitinib's EMA approvalWaiting for erdafitinib's EMA approval
    Read more »
  19. What types of cancer can tazemetostat treat? The latest research.

    Can tazemetostat treat bladder cancer, prostate cancer, and more? Here's the latest research.

    Read more »
  20. Tazemetostat's EMA approval: What if waiting is no option?

    Tazverik seems a long way from EMA approval. If you can't wait, here are all your options to safely get the treatment.

    Read more »
  21. Tofersen's EMA approval: When is it coming (and how to get the medicine in the meantime)

    Get the latest updates on Tofersen's EMA approval timeline and discover alternative ways to access the medicine in the meantime.

    Read more »
  22. Relyvrio's elusive approval in Europe: How to skip the wait

    What does Relyvrio's recent EMA rejection mean for ALS patients in Europe? All you need to know (and what you can do to get the treatment quickly)

    Read more »
  23. Edaravone in Europe: How to get this ALS treatment quickly

    When will Radicut/Radicava(edaravone) be available to ALS patients in Europe and the UK (and what to do in the meantime).

    Read more »
  24. Tyrvaya: When is the first nasal spray for dry eyes coming to Europe?

    When is the first nasal spray for dry eyes coming to Europe (and what to do in the meantime)

    Read more »
  25. Roflumilast Cream in Europe: Approval timelines, efficacy and more

    Topical roflumilast isn't likely to be available in Europe soon. Here's what you can expect, and some solutions for the meantime.

    Read more »
  26. Adagrasib and brain metastases: Does it work, is it better than sotorasib, and how to get it?

    How effective is adagrasib for brain metastases? The latest data, and how to access the treatment quickly.

    Read more »
  27. Is Elahere approved in Europe (and what to do until it is)?

    When are Elahere's EMA and MHRA approvals expected, and what can patients in Europe and the UK do in the meantime.

    Read more »
  28. Can I get lecanemab in the UK? MHRA approval timelines and how to avoid waiting.

    When will Leqembi receive MHRA approval? And how you can access the medicine in the meantime.

    Read more »
  29. Ryzneuta's EMA approval: When is it coming (and how to avoid waiting)

    Ryzneuta's EMA and MHRA approvals seem nowhere in sight. Here's how you can access the medicine without waiting.

    Read more »
  30. Capivasertib's EMA approval: When is it coming, and what to do in the meantime?

    When will capivasertib be available to breast cancer patients in Europe and the UK? Approval status, timelines, and all your options for accessing the medicine quickly.

    Read more »
Page
US 0